drugset / Trial / NCT00435409

A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

NCT00435409

Phase 3 Completed 442 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.

Timeline

Start
2007-02
Primary completion
2009-12
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Capecitabine Small molecule 2000 mg/m2 Oral
Comparator Capecitabine Small molecule 2500 mg/m2 Oral
Subject Sunitinib Small molecule 37.5 mg Oral

Indications